Use of apomorphine in Parkinson's disease

被引:1
|
作者
Giménez-Roldán, S [1 ]
García-Muñozguren, S [1 ]
机构
[1] Univ Madrid, Hosp Gen Gregorio Maranon, Serv Neurol, E-28007 Madrid, Spain
关键词
apomorphine; biphasic dyskinesias; fluctuations; Parkinson's disease;
D O I
10.33588/rn.3507.2002056
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Introduction. Apomorphine is a D-2 dopamine agonist, possibly underused despite its efficacy in situations where other medications have failed or lack of indication for stereotactic surgery. Rapidly effective (between 7 and 10 min) and potency approaching that of levodopa allows apomorphine to reduce reliably severe fluctuations, off-period dystonia, biphasic dyskinesias or such symptoms as dysphagia, anismus of micturition difficulties. Unlike other agonists, apomorphine has a modest capacity to induce neuropsychiatric complications. Brief duration of response (<60 min) and the need of subcutaneous administration represent major difficulties in practice. Objective and development. This review undertake some of the pharmacological properties of this 'orphan drug', its use in practice, and new pathways of development.
引用
收藏
页码:668 / 674
页数:7
相关论文
共 50 条
  • [1] Use of apomorphine in Parkinson's disease
    O'Sullivan, JD
    Lees, AJ
    HOSPITAL MEDICINE, 1999, 60 (11): : 816 - 820
  • [2] Use of apomorphine in Parkinson’s disease
    Fabrizio Stocchi
    Neurological Sciences, 2008, 29 : 383 - 386
  • [3] Use of apomorphine in Parkinson's disease
    Stocchi, Fabrizio
    NEUROLOGICAL SCIENCES, 2008, 29 (Suppl 5) : S383 - S386
  • [4] Perioperative Use of Apomorphine in Parkinson's Disease
    Hilker, R.
    Sixel-Doering, F.
    AKTUELLE NEUROLOGIE, 2011, 38 : S43 - S45
  • [5] Long term use of apomorphine in Parkinson's disease
    Tagaris, G.
    Sakkou, V.
    Alexoudi, A.
    Logiotatos, N.
    Karageorgiou, C.
    PARKINSONISM & RELATED DISORDERS, 2007, 13 : S112 - S112
  • [6] Patient and carer opinions of apomorphine use in Parkinson's disease
    O'Sullivan, S.
    Beddow, S.
    Lambert, P.
    Montgomery, G.
    Singh, J.
    Mills, J.
    Duffy, N.
    EUROPEAN JOURNAL OF NEUROLOGY, 2009, 16 : 545 - 545
  • [7] Patient and carer opinions of apomorphine use in Parkinson's disease
    O'Sullivan, S.
    Beddow, S.
    Lambert, P.
    Montgomery, G.
    Singh, J.
    Mills, J.
    Duffy, N.
    PARKINSONISM & RELATED DISORDERS, 2009, 15 : S112 - S112
  • [8] USE OF APOMORPHINE IN THE TREATMENT OF PARKINSON DISEASE
    TURJANSKI, N
    LEES, AJ
    MEDICINA-BUENOS AIRES, 1990, 50 (04) : 365 - 368
  • [9] Pharmacokinetics of apomorphine in Parkinson's disease
    Gancher, S
    JOURNAL OF NEURAL TRANSMISSION-SUPPLEMENT, 1995, (45): : 137 - 141
  • [10] Subcutaneous apomorphine in Parkinson's disease
    Chaudhuri, KR
    Clough, C
    BMJ-BRITISH MEDICAL JOURNAL, 1998, 316 (7132): : 641 - 641